134 related articles for article (PubMed ID: 11782375)
1. Tumor-targeted gene therapy for nasopharyngeal carcinoma.
Li JH; Chia M; Shi W; Ngo D; Strathdee CA; Huang D; Klamut H; Liu FF
Cancer Res; 2002 Jan; 62(1):171-8. PubMed ID: 11782375
[TBL] [Abstract][Full Text] [Related]
2. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
[TBL] [Abstract][Full Text] [Related]
3. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy.
Chia MC; Shi W; Li JH; Sanchez O; Strathdee CA; Huang D; Busson P; Klamut HJ; Liu FF
Mol Ther; 2004 Jun; 9(6):804-17. PubMed ID: 15194047
[TBL] [Abstract][Full Text] [Related]
4. Minicircle-oriP-IFNγ: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma.
Zuo Y; Wu J; Xu Z; Yang S; Yan H; Tan L; Meng X; Ying X; Liu R; Kang T; Huang W
PLoS One; 2011 May; 6(5):e19407. PubMed ID: 21573215
[TBL] [Abstract][Full Text] [Related]
5. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma.
Weinrib L; Li JH; Donovan J; Huang D; Liu FF
Cancer Gene Ther; 2001 May; 8(5):352-60. PubMed ID: 11477455
[TBL] [Abstract][Full Text] [Related]
7. Minicircle-oriP-miR-31 as a Novel EBNA1-Specific miRNA Therapy Approach for Nasopharyngeal Carcinoma.
Wu J; Tan X; Lin J; Yuan L; Chen J; Qiu L; Huang W
Hum Gene Ther; 2017 May; 28(5):415-427. PubMed ID: 28042945
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP.
Wang L; Shan L; Lo KW; Yin J; Zhang Y; Sun R; Zhong J
J Gene Med; 2008 Oct; 10(10):1124-33. PubMed ID: 18642396
[TBL] [Abstract][Full Text] [Related]
9. Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma.
Li AA; Ng E; Shi W; Lee A; Chia M; Liu TJ; Huang D; O'Sullivan B; Gullane P; Liu FF
Int J Cancer; 2004 Jun; 110(3):452-8. PubMed ID: 15095314
[TBL] [Abstract][Full Text] [Related]
10. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism.
Wang C; Wang H; Zhang Y; Guo W; Long C; Wang J; Liu L; Sun X
Oncol Rep; 2017 Apr; 37(4):2109-2120. PubMed ID: 28259949
[TBL] [Abstract][Full Text] [Related]
11. Potential utility of BimS as a novel apoptotic therapeutic molecule.
Yip KW; Li A; Li JH; Shi W; Chia MC; Rashid SA; Mocanu JD; Louie AV; Sanchez O; Huang D; Busson P; Yeh WC; Gilbert R; O'sullivan B; Gullane P; Liu FF
Mol Ther; 2004 Sep; 10(3):533-44. PubMed ID: 15336653
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies.
Sivachandran N; Sarkari F; Frappier L
PLoS Pathog; 2008 Oct; 4(10):e1000170. PubMed ID: 18833293
[TBL] [Abstract][Full Text] [Related]
13. [Progress of EBNA1/oriP-based plasmid applied in gene therapy].
He J; Zhang ZQ
Sheng Wu Gong Cheng Xue Bao; 2005 May; 21(3):507-10. PubMed ID: 16108385
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of targeted FasL in nasopharyngeal carcinoma.
Li JH; Shi W; Chia M; Sanchez-Sweatman O; Siatskas C; Huang D; Busson P; Klamut H; Yeh WC; Richardson C; O'Sullivan B; Gullane P; Neligan P; Medin J; Liu FF
Mol Ther; 2003 Dec; 8(6):964-73. PubMed ID: 14664799
[TBL] [Abstract][Full Text] [Related]
15. EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy.
Otomo T; Yamamoto S; Morishita R; Kaneda Y
J Gene Med; 2001; 3(4):345-52. PubMed ID: 11529664
[TBL] [Abstract][Full Text] [Related]
16. GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1.
Shen CL; Huang WH; Hsu HJ; Yang JH; Peng CW
Antiviral Res; 2019 Apr; 164():123-130. PubMed ID: 30817940
[TBL] [Abstract][Full Text] [Related]
17. An enhanced EBNA1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells.
Wendelburg BJ; Vos JM
Gene Ther; 1998 Oct; 5(10):1389-99. PubMed ID: 9930345
[TBL] [Abstract][Full Text] [Related]
18. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Judde JG; Spangler G; Magrath I; Bhatia K
Hum Gene Ther; 1996 Mar; 7(5):647-53. PubMed ID: 8845390
[TBL] [Abstract][Full Text] [Related]
19. Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy.
Mocanu JD; Yip KW; Alajez NM; Shi W; Li JH; Lunt SJ; Moriyama EH; Wilson BC; Milosevic M; Lo KW; van Rooijen N; Busson P; Bastianutto C; Liu FF
Mol Ther; 2007 May; 15(5):921-9. PubMed ID: 17356543
[TBL] [Abstract][Full Text] [Related]
20. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.
Nasimuzzaman M; Kuroda M; Dohno S; Yamamoto T; Iwatsuki K; Matsuzaki S; Mohammad R; Kumita W; Mizuguchi H; Hayakawa T; Nakamura H; Taguchi T; Wakiguchi H; Imai S
Mol Ther; 2005 Apr; 11(4):578-90. PubMed ID: 15771960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
